GeoVax to Participate at the World Vaccine Congress with Multiple Presentations
March 30 2023 - 11:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced that it
will be represented in two presentations during the upcoming 23rd
Annual World Vaccine Congress taking place in Washington, DC on
April 3-6, 2023.
Presentation Details
· On
Wednesday, April 5, during the session on Global Health
Preparedness Strategy and Priority Pathogens, Dr. Jason Comer,
Associate Professor, Sealy Institute for Vaccine Sciences,
University of Texas Medical Branch (UTMB), will deliver a
presentation titled, “Vaccines and Immunotherapeutics against Sudan
Ebola Virus.”
Dr. Comer has extensive experience leading medical
countermeasure efficacy studies in biocontainment (BSL-2 through
BSL-4). His presentation will focus on UTMB’s services for
regulated, nonclinical studies, particularly surrounding therapies
and prophylactics for Filoviruses. Dr. Comer’s presentation
will include data from efficacy studies of GeoVax’s vaccine
candidates targeting Marburg virus and Sudan Ebola virus disease
contracted to UTMB through the National Institute of Allergy and
Infectious Disease (NIAID) Preclinical Services.
· On
Thursday, April 6, during the session on Next Generation COVID
Vaccines, Dr. Don Diamond, Professor, Department of Hematology
& Hematopoietic Cell Transplantation, City of Hope, will
deliver a presentation titled, “Covid-19 Vaccine CM04S1; A Superior
Viral Platform Alternative for Eliciting Durable T Cell Responses
in Immunocompromised Hematologic Malignancy Patients.”
Dr. Diamond’s presentation will include a detailed description
of the development and clinical testing of GeoVax’s vaccine
candidate, GEO-CM04S1. The CM04S1 vaccine is an experimental
COVID-19 vaccine based on the use of the MVA viral vector platform,
which presents multiple antigens to the immune system to induce
both antibody and T cell responses. This is a next-generation
vaccine designed to provide continued protection against new and
continually emerging variants of COVID without the need for
repeated modification and updating.
GeoVax is focusing on the clinical development of this vaccine
for use in patients with special medical limitations or needs,
specifically the partially immunocompromised population. These
individuals may not be able to raise or maintain protective
antibody responses following receipt of first-generation mRNA
vaccines, contributing to reduced vaccine efficacy. This includes
patients suffering from and/or being treated for numerous
malignancies, autoimmune disorders, transplant patients, dialysis
patients, and potentially the aging population. The presentation
will include new and unpublished data from the open-label portion
of the Phase 2 trial in patients undergoing hematological cancer
treatment.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in two Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a COVID-19 vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2024 to Jul 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2023 to Jul 2024